PPARa agonist used to decrease levels of triglycerides and total cholesterol and increase levels of HDL. It also induces depolarization of the mitochondrial membrane potential and enhances peroxisome proliferation. (C003B-255530)

Ciprofibrate is a PPARa agonist that exhibits anti-hyperlipidemic activity. Clinically, ciprofibrate decreases levels of triglycerides and total cholesterol and increases levels of HDL. In hepatoma cells, ciprofibrate increases NF-?B DNA binding activity. Additionally, ciprofibrate induces depolarization of the mitochondrial membrane potential, which may be involved in its mechanism of enhancing peroxisome proliferation. Grade: ≥98%

UPC:

51321804

Condition:

New

Weight:

1.00 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

C3260-100 mg

CAS:

52214-84-3